European Union implements Joint Clinical Assessments for drug policy

The European Union has reached a milestone in pharmaceutical policy with the release of the first Joint Clinical Assessment (JCA) under the EU-HTA Regulation. This initiative aims to address delayed availability and unequal access to new medicines across EU member states.

While the European Medicines Agency (EMA) evaluates the benefit-risk ratio of drugs during the authorization process, Health Technology Assessment (HTA) supports national decisions regarding reimbursement, pricing, and treatment guidelines. The new regulation seeks to reduce redundant work across member states by providing a shared assessment of clinical evidence.

By conducting JCAs in parallel with the EMA authorization process, the regulation shifts HTA to an earlier stage in a drug's lifecycle. Experts suggest this may improve the evidence base, as running authorization and HTA processes concurrently increases the incentive for conducting high-quality studies with relevant comparator arms from the outset.